DOCGO INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.93 USD | -0.68% |
|
-3.93% | -47.58% |
| May. 09 | Cantor Fitzgerald Adjusts DocGo Price Target to $5 From $11, Maintains Overweight Rating | MT |
| May. 09 | Deutsche Bank Adjusts DocGo Price Target to $5 From $8.20, Maintains Buy Rating | MT |
Strengths
- The earnings growth currently anticipated by analysts for the coming years is particularly strong.
- The company is in a robust financial situation considering its net cash and margin position.
- The company shows low valuation levels, with an enterprise value at 0.32 times its sales.
- The company appears to be poorly valued given its net asset value.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- According to Standard & Poor's' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
Ratings chart - Surperformance
Sector: Healthcare Facilities & Services
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| -47.58% | 298M | - | ||
| -4.11% | 2.98B | B- | ||
| -.--% | 1.93B | - | ||
| +23.65% | 1.86B | C | ||
| +69.11% | 707M | D+ | ||
| -11.21% | 461M | - | ||
| -19.40% | 174M | - | ||
| -16.45% | 131M | - | ||
| +1.92% | 67.77M | - | - |
Investor Rating
Trading Rating
ESG Refinitiv
-
Financials
Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
Valuation
P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
-
Yield
-
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- DCGO Stock
- Ratings DocGo Inc.
